|
schizophrenia |
70 |
|
first-episode psychosis |
47 |
|
covid-19 |
40 |
|
depression |
40 |
|
negative symptoms |
39 |
|
youth mental health |
35 |
|
psychotic disorders |
34 |
|
early psychosis |
33 |
|
psychosis |
31 |
|
functioning |
28 |
|
predictors |
28 |
|
risk factors |
27 |
|
first-episode schizophrenia |
26 |
|
social unrest |
25 |
|
relapse |
23 |
|
medical sciences |
22 |
|
mental health |
22 |
|
post-traumatic stress disorder |
22 |
|
psychiatry and neurology |
22 |
|
psychopathology |
22 |
|
antipsychotics |
21 |
|
cognitive impairment |
21 |
|
duration of untreated psychosis |
21 |
|
anxiety |
20 |
|
early intervention |
20 |
|
epidemiology |
19 |
|
first episode |
19 |
|
network analysis |
19 |
|
insight |
18 |
|
remission |
18 |
|
stigma |
18 |
|
medication adherence |
17 |
|
rumination |
17 |
|
adolescent |
16 |
|
assessment |
16 |
|
delusional disorder |
16 |
|
depressive symptoms |
16 |
|
functional outcome |
16 |
|
hong kong |
16 |
|
loneliness |
16 |
|
adolescents |
15 |
|
amotivation |
15 |
|
employment |
15 |
|
stress |
15 |
|
avolition |
14 |
|
experience sampling method |
14 |
|
first-episode |
14 |
|
prevalence |
14 |
|
quality of life |
14 |
|
cognition |
13 |
|
outcome |
13 |
|
premorbid adjustment |
13 |
|
self-stigma |
13 |
|
symptomatology |
13 |
|
validation study |
13 |
|
cost-effectiveness |
12 |
|
evaluation |
12 |
|
executive function |
12 |
|
momentary positive affect |
12 |
|
neurocognition |
12 |
|
suicidal ideation |
12 |
|
adherence |
11 |
|
adult |
11 |
|
caregivers |
11 |
|
diminished expression |
11 |
|
long-term outcomes |
11 |
|
longitudinal follow-up |
11 |
|
pattern glare |
11 |
|
perceptual distortions |
11 |
|
processing speed |
11 |
|
prospective follow-up |
11 |
|
self-reference |
11 |
|
young people |
11 |
|
youth |
11 |
|
age of onset |
10 |
|
cognitive functions |
10 |
|
community-based intervention |
10 |
|
discontinuation |
10 |
|
disengagement |
10 |
|
double blind |
10 |
|
f-dopa |
10 |
|
female |
10 |
|
maintenance |
10 |
|
meta-analysis |
10 |
|
positron emission tomography |
10 |
|
randomized controlled trial |
10 |
|
recovery |
10 |
|
relapse prevention |
10 |
|
sex difference |
10 |
|
striatal dopamine capacity synthesis |
10 |
|
treatment adherence |
10 |
|
youth-friendly |
10 |
|
affect |
9 |
|
antidepressants |
9 |
|
antipsychotic |
9 |
|
autism spectrum disorder |
9 |
|
autistic disorder |
9 |
|
bipolar disorder |
9 |
|
cognitive function |
9 |
|
delusions |
9 |
|
dopamine |
9 |
|
early medical intervention - methods - trends |
9 |
|
epidemiological youth |
9 |
|
esm |
9 |
|
hallucination |
9 |
|
health education - methods |
9 |
|
ideas of reference |
9 |
|
internalized stigma |
9 |
|
intervention |
9 |
|
life events |
9 |
|
mental health services - trends |
9 |
|
momentary assessment |
9 |
|
motivational deficits |
9 |
|
program development |
9 |
|
psychotic disorders - therapy |
9 |
|
psychotic-like experiences |
9 |
|
public stigma |
9 |
|
schizotypal personality disorder |
9 |
|
social context |
9 |
|
traumatic events |
9 |
|
treatment outcome |
9 |
|
young adult |
9 |
|
cluster analysis |
8 |
|
corpus striatum |
8 |
|
delusions - diagnosis |
8 |
|
delusions - etiology |
8 |
|
dose-dependent effect |
8 |
|
epidemiological study |
8 |
|
eye-gaze perception |
8 |
|
first episode psychosis |
8 |
|
growth mixture modeling |
8 |
|
interview, psychological - methods |
8 |
|
latent class analysis |
8 |
|
long-term outcome |
8 |
|
maintenance treatment |
8 |
|
mass screening |
8 |
|
mass screening - methods |
8 |
|
mentalization |
8 |
|
mode of onset |
8 |
|
pandemic |
8 |
|
persistent psychotic experience |
8 |
|
population-based |
8 |
|
prospective study |
8 |
|
psychiatric status rating scales |
8 |
|
psychotic disorders - complications |
8 |
|
ptsd symptoms |
8 |
|
raclopride |
8 |
|
schizophrenic psychology |
8 |
|
semantic |
8 |
|
trauma exposure |
8 |
|
age factors |
7 |
|
anti-stigma campaigns |
7 |
|
behavioral symptoms - etiology - psychology - therapy |
7 |
|
chinese |
7 |
|
cognition disorders - etiology |
7 |
|
coping strategies |
7 |
|
correlates |
7 |
|
course |
7 |
|
duration of untreated psychosis (dup) |
7 |
|
effort-cost computation |
7 |
|
extended early intervention |
7 |
|
first-episode schizophrenia spectrum disorder |
7 |
|
follow-up studies |
7 |
|
functional remission |
7 |
|
gender |
7 |
|
help-seeking |
7 |
|
help‐seeking |
7 |
|
humans |
7 |
|
illness disclosure |
7 |
|
late-onset psychosis |
7 |
|
latent class growth analysis |
7 |
|
long-term follow-up |
7 |
|
longitudinal course |
7 |
|
male |
7 |
|
maternal age |
7 |
|
mental disorders |
7 |
|
mental health literacy |
7 |
|
mindfulness |
7 |
|
mortality |
7 |
|
motivational impairment |
7 |
|
neurobiology |
7 |
|
neuropsychological tests |
7 |
|
neuropsychology |
7 |
|
paternal age |
7 |
|
pathways |
7 |
|
persistent primary negative symptoms |
7 |
|
pre-existing mental disorders |
7 |
|
prediction |
7 |
|
predictive value of tests |
7 |
|
pregnancy |
7 |
|
prognosis |
7 |
|
psychiatric patients |
7 |
|
psychosocial |
7 |
|
psychotic disorders - diagnosis |
7 |
|
psychotic disorders - diagnosis - psychology |
7 |
|
ptsd symptoms, women mental health |
7 |
|
real-world functioning |
7 |
|
recurrence |
7 |
|
rehospitalization |
7 |
|
remission induction |
7 |
|
risk taking |
7 |
|
schizophrenia - complications |
7 |
|
schizophrenia - complications - diagnosis - epidemiology - therapy |
7 |
|
sex characteristics |
7 |
|
sex factors |
7 |
|
social support |
7 |
|
sociodemographic correlates |
7 |
|
stability |
7 |
|
stressful life event |
7 |
|
suicide, attempted - psychology |
7 |
|
survey |
7 |
|
time factors |
7 |
|
treatment delay |
7 |
|
violence |
7 |
|
adults |
6 |
|
affective psychoses |
6 |
|
anhedonia |
6 |
|
anxiety disorders |
6 |
|
app |
6 |
|
asia |
6 |
|
asian continental ancestry group |
6 |
|
asociality |
6 |
|
at-risk mental states |
6 |
|
attitude |
6 |
|
at‐risk mental state |
6 |
|
balloon analogue risk task |
6 |
|
categorization |
6 |
|
category fluency |
6 |
|
chinese zodiac signs |
6 |
|
chizophrenia |
6 |
|
clinical high‐risk |
6 |
|
clinical predictors |
6 |
|
clozapine |
6 |
|
clozapine-resistant schizophrenia |
6 |
|
cognitive clusters |
6 |
|
cognitive flexibility |
6 |
|
cognitive heterogeneity |
6 |
|
cognitive insights |
6 |
|
community |
6 |
|
communityolder |
6 |
|
concepts |
6 |
|
coping styles |
6 |
|
culture |
6 |
|
delivery of health care - standards |
6 |
|
dementia |
6 |
|
depressive mood |
6 |
|
development |
6 |
|
digit symbol test |
6 |
|
digital technologies |
6 |
|
early diagnosis |
6 |
|
early intervention service |
6 |
|
early medical intervention - standards |
6 |
|
effort allocation |
6 |
|
effort discounting |
6 |
|
effort-based decision-making |
6 |
|
environmental stressors |
6 |
|
family functioning |
6 |
|
fitmind |
6 |
|
fractionation |
6 |
|
global functioning |
6 |
|
guideline |
6 |
|
health surveys |
6 |
|
history |
6 |
|
hospitalization |
6 |
|
human |
6 |
|
illness attributional belief |
6 |
|
immersive |
6 |
|
incidence |
6 |
|
internal feed-forward |
6 |
|
interview, psychological |
6 |
|
labelling |
6 |
|
letter |
6 |
|
lifetime prevalence |
6 |
|
long-term trajectories |
6 |
|
longitudinal negative symptoms |
6 |
|
major depressive episode |
6 |
|
memory |
6 |
|
mental disorders / epidemiology |
6 |
|
mental health services - standards |
6 |
|
meta analysis |
6 |
|
mhealth |
6 |
|
mindfulness-based intervention |
6 |
|
negative treatment attitude |
6 |
|
neuroleptic agent |
6 |
|
outcomes |
6 |
|
paranoid schizophrenia |
6 |
|
passivity experiences |
6 |
|
path analysis |
6 |
|
physical activity |
6 |
|
pilot |
6 |
|
pilot trial |
6 |
|
population surveys |
6 |
|
predictive validity |
6 |
|
primary negative symptoms |
6 |
|
priority journal |
6 |
|
prodrome |
6 |
|
psychiatric comorbidity |
6 |
|
psychoeducation |
6 |
|
psychological symptoms |
6 |
|
psychosocial functioning |
6 |
|
recommendation |
6 |
|
reliability |
6 |
|
risk aversion |
6 |
|
risky–gains task |
6 |
|
schizophrenia-spectrum disorder |
6 |
|
self-monitoring |
6 |
|
self-reported cognitive complaints |
6 |
|
smartphone |
6 |
|
social anxiety |
6 |
|
social cognition |
6 |
|
social functioning |
6 |
|
stressful life events |
6 |
|
subjective quality of life |
6 |
|
suicidal behaviours |
6 |
|
suicide-related rumination |
6 |
|
switching |
6 |
|
symptomatic remission |
6 |
|
systematic review |
6 |
|
theory of mind |
6 |
|
traumatic stress symptoms |
6 |
|
treatment |
6 |
|
treatment resistant schizophrenia |
6 |
|
treatment-resistant schizophrenia |
6 |
|
ultra-high risk |
6 |
|
validation |
6 |
|
virtual reality |
6 |
|
vocational outcome |
6 |
|
vr |
6 |
|
web-based |
6 |
|
working memory |
6 |
|
10-year follow-up |
5 |
|
10-year outcomes |
5 |
|
1st episode |
5 |
|
adolescent onset |
5 |
|
adult onset |
5 |
|
affiliate stigma |
5 |
|
aggressive behavior |
5 |
|
alogia |
5 |
|
anticholinergic load |
5 |
|
anxiety disorder |
5 |
|
asian network for early psychosis |
5 |
|
at-risk mental state |
5 |
|
attitudes towards medication |
5 |
|
auditory cortex |
5 |
|
auditory hallucination |
5 |
|
blunted affect |
5 |
|
brain size |
5 |
|
caregiver |
5 |
|
caregivers’ distress |
5 |
|
checklist |
5 |
|
chinese population |
5 |
|
civil disorder |
5 |
|
clinical high-risk |
5 |
|
cohort analysis |
5 |
|
compliance |
5 |
|
cortical thickness (brain) |
5 |
|
dangerous |
5 |
|
discrimination |
5 |
|
disease severity |
5 |
|
drug knowledge |
5 |
|
exercise |
5 |
|
face concern |
5 |
|
financial deprivation |
5 |
|
first psychosis |
5 |
|
first-episode mania |
5 |
|
firstepisode psychosis |
5 |
|
first‐episode psychosis |
5 |
|
formal thought disorder |
5 |
|
gender differences |
5 |
|
gender effect |
5 |
|
general self-efficacy |
5 |
|
genetic high-risk |
5 |
|
glucose supplement |
5 |
|
hopelessness |
5 |
|
knowledge about psychosis |
5 |
|
knowledge of medication |
5 |
|
language |
5 |
|
language disorganization |
5 |
|
learned irrelevance |
5 |
|
life expectancy |
5 |
|
media |
5 |
|
media report violent |
5 |
|
mediators |
5 |
|
medication |
5 |
|
medication discontinuation |
5 |
|
medication knowledge |
5 |
|
meta-aggregation |
5 |
|
metabolic screening |
5 |
|
metabolic syndrome |
5 |
|
mood stabilizers |
5 |
|
neurocognitive impairment |
5 |
|
newspapers |
5 |
|
patient demographics |
5 |
|
perceived public stigma |
5 |
|
polypharmacy |
5 |
|
positive symptoms |
5 |
|
premature mortality |
5 |
|
program |
5 |
|
psychiatry |
5 |
|
psychotic disorder |
5 |
|
psychotic-like experience |
5 |
|
qualitative |
5 |
|
qualitative systematic review |
5 |
|
review |
5 |
|
schizophrenia, pandemic |
5 |
|
schizophrenia-spectrum disorders |
5 |
|
school-based programme |
5 |
|
selective attention |
5 |
|
sex differences |
5 |
|
social contact |
5 |
|
social stigma |
5 |
|
stereotyping |
5 |
|
stigma reduction |
5 |
|
structural equation model |
5 |
|
suicidal behavior |
5 |
|
suicide attempt |
5 |
|
symptoms |
5 |
|
syntax |
5 |
|
trial |
5 |
|
video |
5 |
|
years of potential life lost |
5 |
|
youth and adult |
5 |
|
acute coronary syndrome |
4 |
|
cardioprotective medications |
4 |
|
children & adolescents |
4 |
|
congenital malformations |
4 |
|
connectivity concordance mapping |
4 |
|
electronic health record |
4 |
|
fmri |
4 |
|
neonatal outcomes |
4 |
|
obstetric complications |
4 |
|
pharmacoepidemiology |
4 |
|
prescription patters |
4 |
|
psychotherapy |
4 |
|
resting-state |
4 |
|
revascularization |
4 |
|
second-generation antipsychotics |
4 |
|
temporal trends |
4 |
|
treatment inequality |
4 |
|
treatment resistant |
4 |
|
bart 2 |
3 |
|
cardiac heart defects |
3 |
|
complication burden |
3 |
|
diabetes |
3 |
|
diabetes complications |
3 |
|
diabetes mellitus |
3 |
|
ecological momentary assessment |
3 |
|
excess life-years lost |
3 |
|
ischemic stroke |
3 |
|
life years lost |
3 |
|
lithium |
3 |
|
mortality gap |
3 |
|
mortality trend |
3 |
|
mortalityschizophrenia |
3 |
|
non-affective psychoses |
3 |
|
pharmaco-epidemiology |
3 |
|
population-based study |
3 |
|
risky decision-making |
3 |
|
stroke |
3 |
|
teratogenicity |
3 |
|
basal ganglia |
2 |
|
conflict |
2 |
|
curriculum development |
2 |
|
decision making |
2 |
|
economic crisis |
2 |
|
international |
2 |
|
mental illness |
2 |
|
myanmar |
2 |
|
objective cognitive functioning |
2 |
|
population mental health |
2 |
|
post-stroke mortality |
2 |
|
prediction error |
2 |
|
prefrontal cortex |
2 |
|
stroke risk |
2 |
|
subjective cognitive impairments |
2 |
|
teaching methods |
2 |
|
ypll |
2 |
|
adjunctive therapy |
1 |
|
affectivity |
1 |
|
chronic schizophrenia |
1 |
|
cognitive effort |
1 |
|
coping and rehabilitation |
1 |
|
diagnosis, differential |
1 |
|
diagnostic shift |
1 |
|
diagnostic stability |
1 |
|
discounting |
1 |
|
experience sampling |
1 |
|
group music therapy |
1 |
|
music-based intervention |
1 |
|
psychiatric rehabilitation |
1 |
|
psychosocial rehabilitation |
1 |
|
reward processing |
1 |
|
stress reactivity |
1 |
|
transdiagnostic |
1 |
